Management of epilepsy in women

Postgraduate Medical Journal

Volumn 81, Issue 955, 2005, Pages 278-285

  O'Brien, M D ^a   Gilmour White, S K ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DESOGESTREL; ETHINYLESTRADIOL; ETIRACETAM; ETONOGESTREL; FOLIC ACID; GABAPENTIN; GESTAGEN; LAMOTRIGINE; LEVONELLE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; PROGESTERONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VITAMIN K GROUP;

ANENCEPHALUS; ANOXIA; BONE DENSITY; BREAST FEEDING; CATAMENIAL EPILEPSY; CLEFT LIP PALATE; CONGENITAL HEART MALFORMATION; CONTRACEPTION; DELIVERY; DEVELOPMENTAL DISORDER; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG MILK LEVEL; EPILEPSY; FEMALE INFERTILITY; FETAL HYDANTOIN SYNDROME; FETUS DISEASE; GENETIC RISK; HUMAN; HYPEREMESIS GRAVIDARUM; HYPOSPADIAS; MATERNAL DISEASE; MENOPAUSE; MENSTRUAL CYCLE; NEONATAL HEMORRHAGE; NEURAL TUBE DEFECT; OVARY POLYCYSTIC DISEASE; PATIENT COUNSELING; PREGNANCY; PUERPERIUM; REPRODUCTION; REVIEW; SEIZURE; SPINA BIFIDA; TERATOGENICITY;

ANTICONVULSANTS; CHILD; CONTRACEPTIVES, ORAL, COMBINED; DEVELOPMENTAL DISABILITIES; EPILEPSY; FEMALE; FETAL DISEASES; FOLIC ACID; HUMANS; HYPEREMESIS GRAVIDARUM; INFERTILITY, FEMALE; INTRAUTERINE DEVICES; PREGNANCY; PREGNANCY COMPLICATIONS; PROGESTINS; PUERPERAL DISORDERS; VALPROIC ACID; VITAMIN K DEFICIENCY;

EID: 18844430845     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.030221     Document Type: Review

References (106)

1. Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management women with epilepsy. Seizure 1999;8:201-17.
2. Crawford P, Lee P. Gender difference in management af epilepsy-what women are hearing. Seizure 1999;8:135-9.
3. Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-85.
4. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000;41(suppl 1):61-5.
5. Guillebaud J. Contraception: your questions answered. 4th ed. Edinburgh: Churchill Livingstone, 2004:122.
6. Guillebaud J. Contraception: your questions answered. 4th ed. Edinburgh: Churchill Livingstone, 2004:128-9.
7. Guillebaud J. Contraception: your questions answered. 4th ed. Edinburgh: Churchill Livingstone, 2004:195.
8. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy and fetal outcome. Epilepsia 1996;37(suppl 6):34-44.
9. Guillebaud J. Contraception: your questions answered. 4th ed. Edinburgh: Churchill Livingstone, 2004:130.
10. Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47:151-4.
11. Sabers A, Ohman I, Tomson T. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsia 2002;43:47.
12. Guillebaud J. Contraception: your questions answered. 4th ed. Edinburgh: Churchill Livingstone, 2004:294.
13. Reference withdrawn.
14. Gupta C, Osterman J, Santen R, et al. In vivo metabolism of progestins. J Clin Endocrinol Metab 1979;48:816-20.
15. Guillebaud J. Contraception: your questions answered. 4th ed. Edinburgh: Churchill Livingstone, 2004:349.
16. Guillebaud J. Contraception: your questions answered. 4th ed. Edinburgh: Churchill Livingstone, 2004:472.
17. Baunds W, Guillebaud J. Observational series on women using contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002;28:78-80.
18. Wallace H, Shorvon S, Tallis R. Age specific incidence and prevalence of treated epilepsy in an unselected population of 2,052,922 and age specific fertility rates of women with epilepsy. Lancet 1998;352:1970-3.
19. Herzog AG, Coleman AE, Jacobs AR, et al. Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. Epilepsy Behav 2003;4:407-13.
20. Cummings LN, Guidice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995;36:355-9.
21. Bauer J, Burr W, Elger CE. Seizure occurrence during ovulatory and anovulatory cycles in patients with temporal lobe epilepsy. Eur J Neurol 1998;5:83-8.
22. Morrell MJ, Guidice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002;52:704-11.
23. Isojarvi JI, Laatikainen TJ, Knip M, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
24. Isojarvi JI, Rattya J, Myllyla W, et al. Valproate, lamotrigine and insulin mediated risks in women with epilepsy. Ann Neurol 1998;43:440-51.
25. Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001;42:295-304.
26. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs 2003;63:1185-227.
27. Isojarvi JI. Reproductive dysfunction in women with epilepsy. Neurology 2003;61(suppl 2):S27-34.
28. Bauer J, Isojarvi JIT, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 2003;73:121-5.
29. Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta analysis. Drug Saf 2004;27:197-202.
30. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-8.
31. Nakane Y, Okumo T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of anti-epileptic drugs. Epilepsia 1980;21:663-80.
32. Samren EB, van Duijin CM, Christaens GC, et al. Anti-epileptic drug regimes and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-46.
33. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975;87:285-90.
34. DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984;19:473-81.
35. Malm H, Kajante E, Kivirikko S, et al. Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology 2002;59:630-3.
36. Samren EB, van Duijn CM, Hiilesmaa VK, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations. Epilepsia 1997;38:981-90.
37. Morrow JI, Russell AJC, Irwin B, et al. The safety of antiepileptic drugs in pregnancy: results of the UK epilepsy and pregnancy register. (Abstract). Epilepsia 2004;45(suppl 3):57.
38. Mawer G, Clayton-Smith J, Coyle H, et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002;11:1059-311.
39. Kaneko S, Batino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-58.
40. Omtzigt JG, Las FJ, Grobbee DE, et al. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 2):S35-42.
41. Nau H, Zierer R, Spielmann H, et al. Anew model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant rate administration in the mouse using human drug and metabolite concentrations. J Life Sci 1981;29:2803-13.
42. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21.
43. Ohtsuka Y, Silver K, Lopes-Cendes I, et al. Effect of antiepileptic drugs on psychomotor development in offspring of epileptic mothers. (Abstract). Epilepsia 1999;40(suppl 2):296.
44. Gaily E, Kantola SE, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32.
45. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83.
46. Eriksonn K, Viinikainen K, Monkkonen A, et al. The effects of antiepileptic drug exposure in utero to neurological and cognitive functioning of children of school age. (Abstract). Epilepsia 2004;45(suppl 3):57.
47. Adab N, Tudur-Smith C, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Library. Issue 3 Oxford: Update Software, 2004.
48. Committee on the Safety of Medicines. Sodium valproate and prescribing in pregnancy. Current Problems, in Pharmacovigilance 2003;29:6.
49. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000;321:674-5.
50. Weil JG, Cunningham MC, Williamson RR, et al. Eleven year interim results of an international study of pregnancy outcomes following exposure to lamotrigine. (Abstract). Epilepsia 2004;45(suppl 3):57.
51. MRC Vitamin Study Research Group. Prevention of neural tube defects; results of the Medical Research Council vitamin study. Lancet 1991;338:132-7.
52. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptual multivitamin supplementation. N Engl J Med 1992;327:1832-5.
53. Biale Y, Lewenthal M. Effect of folic acid supplementation on congenital malformations due to anticonvulsant drugs. Eur J Obstet Gynecol Reprod Biol 1984;18:211-16.
54. Tomson T, Lindbom U, Berg A. Red cell folate levels in pregnant epileptic women. Eur J Clin Pharmacol 1995;48:305-8.
55. Kirke PN, Molloy AM, Daly LE, et al. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993;86:703-8.
56. Genetics Committee, Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003;25:959-73.
57. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural tube defects with folic acid in China. N Engl J Med 1999;341:1485-90.
58. Smithells RW, Seller MJ, Harris R. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983;i:1027-31.
59. Lucock M. Is folic acid the ultimate functional food component for disease prevention? BMJ 2004;328:211-14.
60. Kelly P, McPartlin J, Goggins M, et al. Unmetabolised folic acid in serum. Am J Clin Nutr 1997;65:1790-5.
61. Wald NJ, Law MR, Morris JK, et al. Quantifying the effect of folic acid. Lancet 2001;358:2069-73.
62. BMA/Royal Pharmaceutical Society of Great Britain British national formulary. Number 48. London: BMA, RPSGB, 2004:457.
63. Hansen DK, Grafton TF. Lack of attenuation of valproate induced effects by folinic acid in rat embryos in vitro. Teratology 1995;52:277-85.
64. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003;61(suppl 2):S23-6.
65. McFayden A, Gledhill J, Whitlow B, et al. First trimester ultrasound screening. BMJ 1998;317:694-5.
66. Samren EB. Maternal epilepsy and major congenital abnormalities. In: Maternal epilepsy and pregnancy outcome. (MD thesis). Rotterdam: Erasmus University, 1998:77-9.
67. Vidovic Ml, Della-Marina BM. Trimestral changes of seizure frequency in pregnant epileptic women. Acta Med Croatica 1994;48:85-7.
68. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61(suppl 2):S35-42.
69. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002;59:251-5.
70. Pennell PB, Montgomery JQ, Clements SD, et al. Lamotrigine clearance markedly increases during pregnancy. (Abstract). Epilepsia 2002;43(suppl 7):234-5.
71. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-3.
72. Betts T, Greenhill L. Use of lamotrigine monotherapy in women who are pregnant: is dose escalation needed during pregnancy? ILEA meeting, Liverpool, Apr, 2001.
73. Berry DJ. The distribution of lamotrigine throughout pregnancy. (Abstract). Ther Drug Monit 1999;21:450.
74. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate and during lactation. Epilepsia 2000;41:709-13.
75. Devinsky O. Patients with refractory seizures. N Engl J Med 1999;340:1565-7.
76. Ramsey RE, Cohen A, Brown MC. Coexisting epilepsy and non-epileptic seizures. In: Rowan AJ, Gates JR, eds. Non-epileptic seizures. Boston: Butterworth-Heinemann, 1993:47-54.
77. Richmond JR, Krishnamoorthy P, Andermann E, et al. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004;190:371-9.
78. Katz JM, Devinsky O. Primary generalised epilepsy; a risk factor for seizures in labour and delivery. Seizure 2003;12:217-19.
79. Terramo K, Hiilesmaa V. Pregnancy and fetal complications in epileptic pregnancies. In: Janz D, Bossi L, Dam M, et al, eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982:53-9.
80. 1 and its implications in fetal haemostasis. Thromb Haemost 1988;60:39-43.
81. Sheorer MJ. Vitamin K. Lancet 1995;345:229-34.
82. Rennie JM, Kelsall AWL. Vitamin K prophylaxis in the newborn. Arch Dis Child 1994;70:248-51.
83. Tin W, Wariyar U, Hey E. Preventing late bleeding in infants with vitamin K deficiency. BMJ 1998;316:230.
84. Golding J, Greenwood R, Birmingham K, et al. Childhood cancer, intramuscular vitamin K and pethidine given during labour. BMJ 1992;305:341-6.
85. McKinney PA, Juszczak E, Findlay E, et al. Case control study of childhood leukaemia and cancer in Scotland: findings for neonatal intramuscular vitamin K. BMJ 1998;316:173-7.
86. Passmore SJ, Draper G, Brownbill P, et al. Case control studies of relation between childhood cancer and neonatal vitamin K administration. BMJ 1998;316:178-84.
87. Passmore SJ, Draper G, Brownbill P, et al. Ecological studies of relation between hospital policies on neonatal vitamin K administration and subsequent occurrence of childhood cancer. BMJ 1998;316:184-9.
88. Parker L, Cole M, Craft AW, et al. Neonatal vitamin K administration and childhood cancer in the north of England. BMJ 1998;316:184-9.
89. Thompson JR, FitzGerald P, Willoughby LN, et al. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case control study. Lancet 2001;358:1935-7.
90. Kaaja E, Kaaja R, Matila R, et al. Enzyme inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002;58:549-53.
91. Anderson GD. Phenobarbital and other barbiturates. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2002:500.
92. Ohman I, Vitolos S, Luef G, et al. Topiramate kinetics during delivery, lactation and in the neonate. Epilepsia 2002;43:1157-60.
93. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam in pregnancy and lactation. (Abstract). Epilepsia 2004;45(suppl 3):58.
94. Betts T, Fox C. Proactive preconceptual counselling for women with epilepsy. Seizure 1999;8:322-7.
95. Harper PS. Practical genetic counselling. 6th ed. London: Arnold, 2004:185.
96. Nashef L. The definitions, aetiologies and diagnosis of epilepsy. In: Shorvon S, Dreifus F, Fish D, et al, eds. The treatment of epilepsy. London: Blackwell, 1996:81.
97. Appleton RE, Chadwick D, Sweeney A. Managing the teenager with epilepsy: paediatric to adult care. Seizure 1997;6:27-30.
98. Jasper JD, Goel R, Einarson A, et al. Effects of framing on terotogenic risk perception in pregnant women. Lancet 2001;358:1237-8.
99. Foldary-Schaefer N, Falcone T. Catamenial epilepsy. Neurology 2003;61(suppl 2):S2-15.
100. Klein P, Herzog AG. Hormonal effects on epilepsy in women. Epilepsia 1998;39(suppl 8):9-16.
101. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy. J Neurol Neurogurg Psychiatry 1984;47:1279-82.
102. Harden CL, Koppel BS, Herzog AG, et al. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology 2003;61:451-5.
103. Harden CL, Pulver MC, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999;40:1402-7.
104. Persson HB, Alberts KA, Farahmand BY, et al. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002;43:768-72.
105. Harden CL. The menopause and bone density issues for women with epilepsy. Neurology 2003;61(suppl 2):S16-22.
106. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5(suppl 2):S41-7.